文献速递肺结节与肺癌

多维游离DNA片段组学检测早期肺癌

Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究纳入350例无癌参与者和432例癌症参与者,利用全基因组测序分析血浆游离DNA片段组学特征,构建堆叠集成模型。该模型在三个验证队列中表现出高敏感性(91.4%、84.7%、92.5%)和高特异性(95.7%、98.6%、94.2%),对I期肺癌敏感性为83.2%,对<1 cm肿瘤敏感性为85.0%。

要点

  • 堆叠集成模型整合五种cfDNA特征和五种机器学习算法,优于单一特征-算法组合。
  • 验证队列中敏感性91.4%-92.5%,特异性94.2%-98.6%,AUC 0.974-0.987。
  • 测序深度降至0.5×时模型性能保持稳定(AUC 0.966-0.971)。

核心结论

  • 基于cfDNA片段组学特征的堆叠集成模型对早期肺癌检测具有优越敏感性,可促进早期诊断。

研究设计与样本

  • 研究纳入350例无癌参与者和432例癌症参与者,血浆cfDNA样本行全基因组测序。
  • 训练队列(癌症113例,健康113例)用于构建模型,三个验证队列用于评估性能。

主要发现

  • 验证队列I敏感性91.4%时特异性95.7%,AUC 0.984。
  • 验证队列II敏感性84.7%时特异性98.6%,AUC 0.987。
  • 额外验证敏感性92.5%时特异性94.2%,AUC 0.974。
  • 测序深度降至0.5×时AUC为0.966-0.971。
  • 在0.66截断值时,I期肺癌敏感性83.2%,<1 cm肿瘤敏感性85.0%。

关键数值与推荐

  • 验证队列I:敏感性91.4%,特异性95.7%,AUC 0.984。
  • 验证队列II:敏感性84.7%,特异性98.6%,AUC 0.987。
  • 额外验证:敏感性92.5%,特异性94.2%,AUC 0.974。
  • 测序深度0.5×时AUC 0.966-0.971。
  • 0.66截断值下I期敏感性83.2%,<1 cm肿瘤敏感性85.0%。

临床怎么用

  • 该cfDNA片段组学集成模型有望用于早期肺癌检测,尤其在I期和<1 cm肿瘤中显示较高敏感性。
  • 模型在较低测序深度下性能稳定,可能有助于降低成本并推广临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Cell-free DNA (cfDNA) analysis holds promise for early detection of lung cancer and benefits patients with higher survival. However, the detection sensitivity of previous cfDNA-based studies was still low to suffice for clinical use, especially for early-stage tumors. Objectives: Establish an accurate and affordable approach for early-stage lung cancer detection by integrating cfDNA fragmentomics and machine learning models. Methods: This study included 350 participants without cancer and 432 participants with cancer. The participants' plasma cfDNA samples were profiled by whole-genome sequencing. Multiple cfDNA features and machine learning models were compared in the training cohort to achieve an optimal model. Model performance was evaluated in three validation cohorts. Measurements and Main Results: A stacked ensemble model integrating five cfDNA features and five machine learning algorithms constructed in the training cohort (cancer: 113; healthy: 113) outperformed all the models built on individual feature-algorithm combinations. This integrated model yielded superior sensitivities of 91.4% at 95.7% specificity for cohort validation I (area under the curve [AUC], 0.984), 84.7% at 98.6% specificity for validation II (AUC, 0.987), and 92.5% at 94.2% specificity for additional validation (AUC, 0.974), respectively. The model's high performance remained consistent when sequencing depth was down to 0.5× (AUC, 0.966-0.971). Furthermore, our model is sensitive to identifying early pathological features (83.2% sensitivity for stage I, 85.0% sensitivity for <1 cm tumor at the 0.66 cutoff). Conclusions: We have established a stacked ensemble model using cfDNA fragmentomics features and achieved superior sensitivity for detecting early-stage lung cancer, which could promote early diagnosis and benefit more patients.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Wang S, Meng F, Li M, et al. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer. Am J Respir Crit Care Med. 2023. PMID: 36346614. doi:10.1164/rccm.202109-2019OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。